<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> contributes to the excess morbidity and mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Exogenous glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) lowers postprandial glycaemia predominantly by slowing gastric emptying </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the effects of GLP-1 on postprandial <z:chebi fb="23" ids="18059">lipid</z:chebi> levels and gastric emptying were assessed </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: 14 healthy male volunteers were studied with an i.v. infusion of GLP-1 (1.2 pmol kg(-1) min(-1)) or placebo over 390 min in the fasting state </plain></SENT>
<SENT sid="4" pm="."><plain>A solid test meal was served and gastric emptying was determined using a (13)C-labelled <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="25646">octanoate</z:chebi> breath test </plain></SENT>
<SENT sid="5" pm="."><plain>Venous blood was drawn frequently for measurement of <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, glucagon, GLP-1, <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and NEFA </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: GLP-1 administration lowered fasting and postprandial glycaemia (p&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Gastric emptying was delayed by GLP-1 compared with placebo (p&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>During GLP-1 administration, insulin secretory responses were higher in the fasting state but lower after meal ingestion </plain></SENT>
<SENT sid="9" pm="."><plain>After meal ingestion, <z:chebi fb="0" ids="17855">triglyceride</z:chebi> plasma levels increased by 0.33+/-0.14 mmol/l in the placebo experiments (p&lt;0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, the postprandial increase in <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels was completely abolished by GLP-1 (change in <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, -0.023+/-0.045 mmol/l; p&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>During GLP-1 infusion, plasma concentrations of NEFA were suppressed by 39% in the fasting state (p&lt;0.01) and by 31+/-5% after meal ingestion (p&lt;0.01) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: GLP-1 improves postprandial <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">lipidaemia</z:e>, presumably as a result of <z:mp ids='MP_0009854'>delayed gastric emptying</z:mp> and insulin-mediated inhibition of lipolysis </plain></SENT>
<SENT sid="13" pm="."><plain>Thus, by lowering both <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> concentrations, GLP-1 administration may reduce the cardiovascular risk in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>